Comparative Pharmacology
Head-to-head clinical analysis: PEDIAMYCIN 400 versus R P MYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIAMYCIN 400 versus R P MYCIN.
PEDIAMYCIN 400 vs R-P MYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
400 mg orally every 6 hours for 10 days.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
None Documented
None Documented
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Renal (60-80% unchanged), biliary/fecal (15-20%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic